Vascular tissue engineering: Towards the next generation vascular grafts

Advanced Drug Delivery Reviews

Volumn 63, Issue 4, 2011, Pages 312-323

  Naito, Yuji ^a   Shinoka, Toshiharu ^a   Duncan, Daniel ^a   Hibino, Narutoshi ^a   Solomon, Daniel ^a   Cleary, Muriel ^a   Rathore, Animesh ^a   Fein, Corey ^a   Church, Spencer ^a   Breuer, Christopher ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow derived mononuclear cells; Extracellular matrix; Stem cells; Translational research; Vascular remodeling; Vascular tissue engineering

Indexed keywords

EXTRACELLULAR MATRIX; MONONUCLEAR CELLS; TRANSLATIONAL RESEARCH; VASCULAR REMODELING; VASCULAR TISSUE ENGINEERING;

BONE; CARDIOVASCULAR SURGERY; EXPERIMENTS; SCAFFOLDS (BIOLOGY); STEM CELLS; TISSUE;

GRAFTS;

MICRORNA; POLY(3 HYDROXYBUTYRIC ACID); POLYCAPROLACTONE; POLYGLYCOLIC ACID; POLYHYDROXYALKANOIC ACID; POLYLACTIC ACID; TISSUE SCAFFOLD;

ADSORPTION KINETICS; ARTERIOVENOUS SHUNT; BIODEGRADABILITY; BIOMECHANICS; BLOOD VESSEL GRAFT; BONE MARROW DERIVED MONONUCLEAR CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SURGERY; CELL DIFFERENTIATION; CELL LINEAGE; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; ELECTROSPINNING; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEASIBILITY STUDY; FIBROBLAST; FOREIGN BODY; GENETIC MANIPULATION; GIANT CELL; GRAFT PATENCY; HEMATOPOIETIC STEM CELL; HEMODIALYSIS; HUMAN; INFECTION RISK; KIDNEY FAILURE; MACROPHAGE ACTIVATION; MECHANOTRANSDUCTION; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; NANOFABRICATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SOMATIC CELL; STENOSIS; THROMBOGENICITY; TISSUE ENGINEERING; VISCOELASTICITY;

ANIMALS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARDIOVASCULAR DISEASES; GRAFT OCCLUSION, VASCULAR; HUMANS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 79957739279     PISSN: 0169409X     EISSN: 0169409X     Source Type: Journal    
DOI: 10.1016/j.addr.2011.03.001     Document Type: Review

References (120)

1. Langer R., Vacanti J.P. Tissue engineering. Science 1993, 260(5110):920-926.
2. Fuchs V.R. New priorities for future biomedical innovations. N. Engl. J. Med. 2010, 363(8):704-706.
3. Shin'oka T., et al. Transplantation of a tissue-engineered pulmonary artery. N. Engl. J. Med. 2001, 344(7):532-533.
4. L'Heureux N., et al. Tissue-engineered blood vessel for adult arterial revascularization. N. Engl. J. Med. 2007, 357(14):1451-1453.
5. Priya S.G., et al. Skin tissue engineering for tissue repair and regeneration. Tissue Eng. B Rev. 2008, 14(1):105-118.
6. Ahmed T.A., Hincke M.T. Strategies for articular cartilage lesion repair and functional restoration. Tissue Eng. B Rev. 2010, 16(3):305-329.
7. Khademhosseini A., et al. Microscale technologies for tissue engineering and biology. Proc. Natl Acad. Sci. U.S.A. 2006, 103(8):2480-2487.
8. Piterina A.V., et al. ECM-based materials in cardiovascular applications: inherent healing potential and augmentation of native regenerative processes. Int. J. Mol. Sci. 2009, 10(10):4375-4417.
9. Bell E. Tissue engineering in perspective. Principle of Tissue Engineering 2000, xxxv. Academic Press, San Diego, CA. R.T. Lanza, R. Langer, J.P. Vacanti (Eds.).
10. Walles T., et al. Functional neointima characterization of vascular prostheses in human. Ann. Thorac. Surg. 2004, 77(3):864-868.
11. Clowes A.W., et al. Mechanisms of arterial graft healing. Rapid transmural capillary ingrowth provides a source of intimal endothelium and smooth muscle in porous PTFE prostheses. Am. J. Pathol. 1986, 123(2):220-230.
12. Herring M., et al. A single-staged technique for seeding vascular grafts with autogenous endothelium. Surgery 1978, 84(4):498-504.
13. Deutsch M., et al. Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience. Surgery 1999, 126(5):847-855.
14. Rosenman J.E., et al. Kinetics of endothelial cell seeding. J. Vasc. Surg. 1985, 2(6):778-784.
15. Herring M., et al. Endothelial seeding of polytetrafluoroethylene femoral popliteal bypasses: the failure of low-density seeding to improve patency. J. Vasc. Surg. 1994, 20(4):650-655.
16. Jensen N., et al. Endothelial cell seeded dacron aortobifurcated grafts: platelet deposition and long-term follow-up. J. Cardiovasc. Surg. 1994, 35(5):425-429. (Torino).
17. Bordenave L., et al. In vitro endothelialized ePTFE prostheses: clinical update 20years after the first realization. Clin. Hemorheol. Microcirc. 2005, 33(3):227-234.
18. Zilla P., et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J. Vasc. Surg. 1994, 19(3):540-548.
19. Noishiki Y., et al. Choice, isolation, and preparation of cells for bioartificial vascular grafts. Artif. Organs 1998, 22(1):50-62.
20. Yue X., et al. Smooth muscle cell seeding in biodegradable grafts in rats: a new method to enhance the process of arterial wall regeneration. Surgery 1988, 103(2):206-212.
21. Niklason L.E., et al. Functional arteries grown in vitro. Science 1999, 284(5413):489-493.
22. McAllister T.N., et al. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study. Lancet 2009, 373(9673):1440-1446.
23. Eberli D., Atala A. Tissue engineering using adult stem cells. Meth. Enzymol. 2006, 420:287-302.
24. Matsumura G., et al. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. Circulation 2003, 108(14):1729-1734.
25. Rahkonen O., et al. Mice with a deletion in the first intron of the Col1a1 gene develop age-dependent aortic dissection and rupture. Circ. Res. 2004, 94(1):83-90.
26. Lucero H.A., Kagan H.M. Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell. Mol. Life Sci. 2006, 63(19-20):2304-2316.
27. Kielty C.M., et al. Elastic fibres. J. Cell Sci. 2002, 115(Pt 14):2817-2828.
28. Rodgers U.R., Weiss A.S. Cellular interactions with elastin. Pathol. Biol. 2005, 53(7):390-398. (Paris).
29. Li D.Y., et al. Elastin is an essential determinant of arterial morphogenesis. Nature 1998, 393(6682):276-280.
30. Yamada K.M., Kennedy D.W. Dualistic nature of adhesive protein function: fibronectin and its biologically active peptide fragments can autoinhibit fibronectin function. J. Cell Biol. 1984, 99(1 Pt 1):29-36.
31. Valenick L.V., et al. Fibronectin fragmentation promotes alpha4beta1 integrin-mediated contraction of a fibrin-fibronectin provisional matrix. Exp. Cell Res. 2005, 309(1):48-55.
32. Chamley-Campbell J., et al. The smooth muscle cell in culture. Physiol. Rev. 1979, 59(1):1-61.
33. Hedin U., Thyberg J. Plasma fibronectin promotes modulation of arterial smooth-muscle cells from contractile to synthetic phenotype. Differentiation 1987, 33(3):239-246.
34. Qin H., et al. Effects of extracellular matrix on phenotype modulation and MAPK transduction of rat aortic smooth muscle cells in vitro. Exp. Mol. Pathol. 2000, 69(2):79-90.
35. Yamaguchi Y., et al. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990, 346(6281):281-284.
36. Hildebrand A., et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem. J. 1994, 302(Pt 2):527-534.
37. Peppas N.A., Langer R. New challenges in biomaterials. Science 1994, 263(5154):1715-1720.
38. Saltzman W.M. Cell interaction with polymers. Principle of Tissue Engineering 2000, Academic Press, San Diego. R.T. Lanza, R. Langer, J.P. Vacanti (Eds.).
39. Pachence J.M., Kohn J. Biodegradable polymers. Principle of Tissue Engineering 2000, 263-277. Academic Press, San Diego, CA. R.T. Lanza, R. Langer, J.P. Vacanti (Eds.).
40. Pitt C.G., et al. Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists. NIDA Res. Monogr. 1981, 28:232-253.
41. Gogolewski S., et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J. Biomed. Mater. Res. 1993, 27(9):1135-1148.
42. Madden R.L., et al. Experience with cryopreserved cadaveric femoral vein allografts used for hemodialysis access. Ann. Vasc. Surg. 2004, 18(4):453-458.
43. Dahl S.L., et al. Readily available tissue-engineered vascular grafts. Sci. Transl. Med. 2011, 3(68):68ra9.
44. Konuma T., et al. Performance of CryoValve SG decellularized pulmonary allografts compared with standard cryopreserved allografts. Ann. Thorac. Surg. 2009, 88(3):849-854. discussion 554-5.
45. Simon P., et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur. J. Cardiothorac. Surg. 2003, 23(6):1002-1006.
46. Roh J.D., et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc. Natl Acad. Sci. U.S.A. 2010, 107(10):4669-4674.
47. Jenney C.R., Anderson J.M. Adsorbed serum proteins responsible for surface dependent human macrophage behavior. J. Biomed. Mater. Res. 2000, 49(4):435-447.
48. Brodbeck W.G., et al. Effects of adsorbed heat labile serum proteins and fibrinogen on adhesion and apoptosis of monocytes/macrophages on biomaterials. J. Mater. Sci. Mater. Med. 2003, 14(8):671-675.
49. Hanker J.S., Giammara B.L. Biomaterials and biomedical devices. Science 1988, 242(4880):885-892.
50. Janatova J. Activation and control of complement, inflammation, and infection associated with the use of biomedical polymers. ASAIO J. 2000, 46(6):S53-S62.
51. Esche C., et al. Chemokines: key players in innate and adaptive immunity. J. Invest. Dermatol. 2005, 125(4):615-628.
52. Brodbeck W.G., Anderson J.M. Giant cell formation and function. Curr. Opin. Hematol. 2009, 16(1):53-57.
53. DeFife K.M., et al. Interleukin-13 induces human monocyte/macrophage fusion and macrophage mannose receptor expression. J. Immunol. 1997, 158(7):3385-3390.
54. Apostolopoulos V., McKenzie I.F. Role of the mannose receptor in the immune response. Curr. Mol. Med. 2001, 1(4):469-474.
55. Henson P.M. The immunologic release of constituents from neutrophil leukocytes. II. Mechanisms of release during phagocytosis, and adherence to nonphagocytosable surfaces. J. Immunol. 1971, 107(6):1547-1557.
56. Mills C.D., et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 2000, 164(12):6166-6173.
57. Tang L., et al. Molecular determinants of acute inflammatory responses to biomaterials. J. Clin. Invest. 1996, 97(5):1329-1334.
58. Badylak S.F., Gilbert T.W. Immune response to biologic scaffold materials. Semin. Immunol. 2008, 20(2):109-116.
59. Langille B.L., O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986, 231(4736):405-407.
60. Ando J., et al. Shear stress inhibits adhesion of cultured mouse endothelial cells to lymphocytes by downregulating VCAM-1 expression. Am. J. Physiol. 1994, 267(3 Pt 1):C679-C687.
61. Topper J.N., et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl Acad. Sci. U.S.A. 1996, 93(19):10417-10422.
62. Bao X., et al. Temporal gradient in shear but not steady shear stress induces PDGF-A and MCP-1 expression in endothelial cells: role of NO, NF kappa B, and egr-1. Arterioscler. Thromb. Vasc. Biol. 1999, 19(4):996-1003.
63. Halka A.T., et al. The effects of stretch on vascular smooth muscle cell phenotype in vitro. Cardiovasc. Pathol. 2008, 17(2):98-102.
64. Ingber D.E. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ. Res. 2002, 91(10):877-887.
65. Watanabe M., et al. Tissue-engineered vascular autograft: inferior vena cava replacement in a dog model. Tissue Eng. 2001, 7(4):429-439.
66. Shinoka T., et al. Creation of viable pulmonary artery autografts through tissue engineering. J. Thorac. Cardiovasc. Surg. 1998, 115(3):536-545. discussion 545-6.
67. Naito Y., et al. Successful clinical application of tissue-engineered graft for extracardiac Fontan operation. J. Thorac. Cardiovasc. Surg. 2003, 125(2):419-420.
68. Shin'oka T., et al. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J. Thorac. Cardiovasc. Surg. 2005, 129(6):1330-1338.
69. Hibino N., et al. Late-term results of tissue-engineered vascular grafts in humans. J. Thorac. Cardiovasc. Surg. 2010, 139(2):431-436. 436 e1-2.
70. L'Heureux N., et al. A completely biological tissue-engineered human blood vessel. FASEB J. 1998, 12(1):47-56.
71. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2):215-233.
72. Landgraf P., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129(7):1401-1414.
73. Zhao Y., et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129(2):303-317.
74. Boettger T., et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J. Clin. Invest. 2009, 119(9):2634-2647.
75. McKee J.A., et al. Human arteries engineered in vitro. EMBO Rep. 2003, 4(6):633-638.
76. Shao R., Guo X. Human microvascular endothelial cells immortalized with human telomerase catalytic protein: a model for the study of in vitro angiogenesis. Biochem. Biophys. Res. Commun. 2004, 321(4):788-794.
77. Case J., et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp. Hematol. 2007, 35(7):1109-1118.
78. Asahara T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275(5302):964-967.
79. Peichev M., et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95(3):952-958.
80. Prater D.N., et al. Working hypothesis to redefine endothelial progenitor cells. Leukemia 2007, 21(6):1141-1149.
81. Ingram D.A., et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104(9):2752-2760.
82. Doetschman T.C., et al. The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J. Embryol. Exp. Morphol. 1985, 87:27-45.
83. Thomson J.A., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282(5391):1145-1147.
84. Wang R., et al. Embryonic stem cell-derived cystic embryoid bodies form vascular channels: an in vitro model of blood vessel development. Development 1992, 114(2):303-316.
85. Yamashita J., et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 2000, 408(6808):92-96.
86. Schuldiner M., et al. Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc. Natl Acad. Sci. U.S.A. 2000, 97(21):11307-11312.
87. Davis G.E., Senger D.R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97(11):1093-1107.
88. McCloskey K.E., et al. Use of embryonic stem cell-derived endothelial cells as a cell source to generate vessel structures in vitro. Tissue Eng. 2005, 11(3-4):497-505.
89. Shen G., et al. Tissue engineering of blood vessels with endothelial cells differentiated from mouse embryonic stem cells. Cell Res. 2003, 13(5):335-341.
90. Levenberg S., et al. Endothelial cells derived from human embryonic stem cells. Proc. Natl Acad. Sci. U.S.A. 2002, 99(7):4391-4396.
91. Frankel M.S. In search of stem cell policy. Science 2000, 287(5457):1397.
92. Pittenger M.F., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
93. Bernacki S.H., et al. Isolation of human mesenchymal stem cells from bone and adipose tissue. Meth. Cell Biol. 2008, 86:257-278.
94. Kuwana M., et al. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J. Leukoc. Biol. 2003, 74(5):833-845.
95. Wang J.F., et al. Mesenchymal stem/progenitor cells in human umbilical cord blood as support for ex vivo expansion of CD34(+) hematopoietic stem cells and for chondrogenic differentiation. Haematologica 2004, 89(7):837-844.
96. Campagnoli C., et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001, 98(8):2396-2402.
97. In 't Anker P.S., et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003, 102(4):1548-1549.
98. Abedin M., et al. Mesenchymal stem cells and the artery wall. Circ. Res. 2004, 95(7):671-676.
99. O'Cearbhaill E.D., et al. Behavior of human mesenchymal stem cells in fibrin-based vascular tissue engineering constructs. Ann. Biomed. Eng. 2010, 38(3):649-657.
100. Lin H., et al. Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells. J. Cell. Physiol. 2008, 216(2):458-468.
101. Wang H., et al. Shear stress induces endothelial differentiation from a murine embryonic mesenchymal progenitor cell line. Arterioscler. Thromb. Vasc. Biol. 2005, 25(9):1817-1823.
102. Gong Z., Niklason L.E. Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs). FASEB J. 2008, 22(6):1635-1648. Epub 2008 Jan 16.
103. Jiang Y., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418(6893):41-49.
104. Iso Y., et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem. Biophys. Res. Commun. 2007, 354(3):700-706.
105. Prockop D.J. "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin. Pharmacol. Ther. 2007, 82(3):241-243.
106. Mirza A., et al. Undifferentiated mesenchymal stem cells seeded on a vascular prosthesis contribute to the restoration of a physiologic vascular wall. J. Vasc. Surg. 2008, 47(6):1313-1321.
107. Zhang W.J., et al. Tissue engineering of blood vessel. J. Cell. Mol. Med. 2007, 11(5):945-957.
108. Takahashi K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131(5):861-872.
109. Yu J., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318(5858):1917-1920.
110. Seki T., et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010, 7(1):11-14.
111. Okita K., et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322(5903):949-953.
112. Greiner A., Wendorff J.H. Electrospinning: a fascinating method for the preparation of ultrathin fibers. Angew. Chem. Int. Ed Engl. 2007, 46(30):5670-5703.
113. Kumbar S.G., et al. Electrospun nanofiber scaffolds: engineering soft tissues. Biomed. Mater. 2008, 3(3):034002.
114. He W., et al. Fabrication and endothelialization of collagen-blended biodegradable polymer nanofibers: potential vascular graft for blood vessel tissue engineering. Tissue Eng. 2005, 11(9-10):1574-1588.
115. Kannan R.Y., et al. The antithrombogenic potential of a polyhedral oligomeric silsesquioxane (POSS) nanocomposite. Biomacromolecules 2006, 7(1):215-223.
116. Matsuda T., et al. Mechano-active scaffold design of small-diameter artificial graft made of electrospun segmented polyurethane fabrics. J. Biomed. Mater. Res. A 2005, 73(1):125-131.
117. Courtney T., et al. Design and analysis of tissue engineering scaffolds that mimic soft tissue mechanical anisotropy. Biomaterials 2006, 27(19):3631-3638.
118. Stankus J.J., et al. Fabrication of cell microintegrated blood vessel constructs through electrohydrodynamic atomization. Biomaterials 2007, 28(17):2738-2746.
119. Bashur C.A., et al. Effect of fiber diameter and alignment of electrospun polyurethane meshes on mesenchymal progenitor cells. Tissue Eng. A 2009, 15(9):2435-2445.
120. Mei Y., et al. Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nat. Mater. 2010, 9(9):768-778.